Cargando…
Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation
Despite efforts to enhance enrollment and the merger of national cooperative groups, < 5% of patients with cancer will enroll into a clinical trial. Additionally, clinical trials are affected by a lack of diversity inclusive of minority patients, rural residents, or low-income individuals. COVID-...
Autores principales: | Eng, Cathy, Chen, Emerson Y., Rogers, Jane, Lewis, Mark, Strosberg, Jonathan, Thota, Ramya, Krishnamurthi, Smitha, Oberstein, Paul, Govindarajan, Rang, Buchschacher, Gary, Patel, Sandip, Sohal, Davendra, Al-Toubah, Taymeyah, Philip, Philip, Dasari, Arvind, Kennecke, Hagan, Stein, Stacey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791825/ https://www.ncbi.nlm.nih.gov/pubmed/33534616 http://dx.doi.org/10.1200/OP.20.00701 |
Ejemplares similares
-
What is the role of checkpoint inhibitors in neuroendocrine neoplasms?
por: Al-Toubah, Taymeyah, et al.
Publicado: (2020) -
Chemotherapy in Neuroendocrine Tumors
por: Das, Satya, et al.
Publicado: (2021) -
Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors
por: Al-Toubah, Taymeyah, et al.
Publicado: (2022) -
Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
por: Al-Toubah, Taymeyah, et al.
Publicado: (2023) -
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
por: Vijayvergia, Namrata, et al.
Publicado: (2020)